NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025
NHS England · awarded 1 July 2025
Who
| Buyer | NHS England Runcorn |
|---|---|
| Suppliers |
Abbvie Ltd Accord-UK Ltd Alexion Pharmaceuticals Amgen Ltd Biogen Celltrion Healthcare United Kingdom Limited CuraTeQ Biologics s.r.o. Dr.Reddy's Laboratories (UK) Limited Fresenius Kabi Limited GlaxoSmithKline UK Limited Janssen-Cilag Ltd Organon Pharmaceuticals UK Ltd Orifarm UK Pfizer Ltd Roche Products Ltd Samsung Bioepis UK Ltd Sandoz Ltd Sobi (Swedish Orphan Biovitrum Ltd) Takeda UK Ltd Thornton and Ross Ltd Zentiva Pharma UK Ltd |
| Category | goods |
| Classification | Pharmaceutical products CPV 33600000 |
| Notice published | 29 July 2025 |
What it is for
NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.
Read the original award notice on Contracts Finder →
Other contracts from this buyer
1269 awards on file, worth £50.2bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 4 Mar 2026 | New Hospital Programme - Hospital 2.0 Alliance (H2A) FrameworkEngland | NHS England | Willmott Dixon Construction Limited +9 | £37.0bn |
| 24 Mar 2025 | NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands | NHS England | CSL Behring UK Ltd +71 | £1.2bn |
| 1 Jul 2025 | NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | NHS England | Biogen +20 | £986.3m |
| 19 Dec 2024 | NHS Framework Agreement for Human Albumin & Normal and Anti-D ImmunoglobulinScotland | NHS England | CSL Behring UK Ltd +5 | £905.2m |
| 31 May 2024 | NHS Framework - Blood Disorders including Haemophilia A and B - July 2024East Midlands | NHS England | Pfizer Ltd +8 | £765.0m |
Everything NHS England has awarded →
Other contracts won by this supplier
8 awards on file, worth £2.1bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 1 Jul 2025 | NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | NHS England | Biogen +20 | £986.3m |
| 25 Jul 2024 | NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024 | NHS England | Bayer Plc +8 | £416.8m |
| 22 Jul 2024 | NHS Branded Medicines Tranche Framework for London and South of EnglandEast Midlands | NHS England | Sun Pharma UK Ltd +28 | £381.0m |
| 25 Jun 2025 | NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National | NHS England | Roche Products Ltd +27 | £261.9m |
| 2 Feb 2023 | 0981 Bio-Waste Treatment, Transfer and Transport ServicesSouth East | Essex County Council | Biogen (UK) Ltd +4 | £30.0m |